Vancomycin is a glycopeptide antibiotic commonly used in the management of methicillin-resistant Staphylococcus aureus infection. The recent increase in prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin has prompted experts to advocate for higher target trough serum concentrations. This study aimed to evaluate the potential consequences of more aggressive vancomycin therapy, by examining the association between higher serum concentrations and acute kidney injury (AKI) in a population of critically ill patients. We collected data for all patients who received vancomycin over a five-year period and evaluated the prevalence of new-onset AKI using the Risk, Injury, Failure, Loss and End-stage (RIFLE) kidney disease criteria. One-hundred and fifty-nine patients provided complete data, with 8.8% manifesting new onset AKI while receiving vancomycin. The median age was 57 (44 to 68) years, while the median trough serum concentration was 16 (10 to 19) mg/l. Multivariate logistic regression analysis identified mean trough concentration (OR=1.174, P=0.024), APACHE II score (OR=1.141, P=0.012) and simultaneous aminoglycoside prescription (OR=18.896, P=0.002) as significant predictors of AKI. These data suggest higher trough vancomycin serum concentrations are associated with greater odds of AKI in the critically ill.
LiuC., BayerA., CosgroveS.E., DaumR.S., FridkinS.K., GorwitzR.J.Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.Clin Infect Dis2011; 52: e18–e55.
2.
van HalS.J., PatersonD.L., LodiseT.P.Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter.Antimicrob Agents Chemother2013; 57: 734–744.
3.
RybakM.J., LomaestroB.M., RotschaferJ.C., MoelleringR.C., CraigW.A., BilleterM.Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.Clin Infect Dis2009; 49: 325–327.
4.
American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia.Am J Respir Crit Care Med2005; 171: 388–416.
5.
Wong-BeringerA., JooJ., TseE., BeringerP.Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy.Int J Antimicrob Agents2011; 37: 95–101.
6.
PritchardL., BakerC., LeggettJ., SehdevP., BrownA., BayleyK.B.Increasing vancomycin serum trough concentrations and incidence of nephrotoxicity.Am J Med2010; 123: 1143–1149.
7.
LodiseT.P., LomaestroB., GravesJ., DrusanoG.L.Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity.Antimicrob Agents Chemother2008; 52: 1330–1336.
8.
DennenP., DouglasI.S., AndersonR.Acute kidney injury in the intensive care unit: an update and primer for the intensivist.Crit Care Med2010; 38: 261–275.
9.
KnausW.A., DraperE.A., WagnerD.P., ZimmermanJ.E.APACHE II: a severity of disease classification system.Crit Care Med1985; 13: 818–829.
10.
LodiseT.P., PatelN., LomaestroB.M., RodvoldK.A., DrusanoG.L.Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.Clin Infect Dis2009; 49: 507–514.
11.
RybakM., LomaestroB., RotschaferJ.C., MoelleringR.Jr., CraigW., BilleterM.Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.Am J Health Syst Pharm2009; 66: 82–98.
12.
BellomoR., RoncoC., KellumJ.A., MehtaR.L., PalevskyP.Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.Crit Care2004; 8: R204–R212.
13.
PickeringJ.W., EndreZ.H.Back-calculating baseline creatinine with MDRD misclassifies acute kidney injury in the intensive care unit.Clin J Am Soc Nephrol2010; 5: 1165–1173.
14.
MooreE.M., BellomoR., NicholA.D.The meaning of acute kidney injury and its relevance to intensive care and anaesthesia.Anaesth Intensive Care2012; 40: 929–948.
15.
HidayatL.K., HsuD.I., QuistR., ShrinerK.A., Wong-BeringerA.High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity.Arch Intern Med2006; 166: 2138–2144.
16.
RybakM.J., AlbrechtL.M., BoikeS.C., ChandrasekarP.H.Nephrotoxicity of vancomycin, alone and with an aminoglycoside.J Antimicrob Chemother1990; 25: 679–687.
17.
FarberB.F., MoelleringR.C.Jr.Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981.Antimicrob Agents Chemother1983; 23: 138–141.
18.
RoncoC, KellumJ.A., BellomoR., HouseA.A.Potential interventions in sepsis-related acute kidney injury.Clin J Am Soc Nephrol2008; 3: 531–544.
19.
del Mar Fernandez de Gatta GarciaM., RevillaN., CalvoM.V., Dominguez-GilA., Sanchez NavarroA.Pharmacokinetic/ pharmacodynamic analysis of vancomycin in ICU patients.Intensive Care Med2007; 33: 279–285.
20.
Launay-VacherV., IzzedineH., MercadalL., DerayG.Clinical review: use of vancomycin in haemodialysis patients.Crit Care2002; 6: 313–316.
21.
MatzkeG.R., ZhanelG.G., GuayD.R.Clinical pharmacokinetics of vancomycin.Clin Pharmacokinet1986; 11: 257–282.
22.
JeffresM.N., IsakowW., DohertyJ.A., MicekS.T., KollefM.H.A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia.Clin Ther2007; 29: 1107–1115.
23.
HazlewoodK.A., BrouseS.D., PitcherW.D., HallR.G.Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?Am J Med2010; 123: 182.e1–7.
24.
PalmieriT., LavrentievaA., GreenhalghD.G.Acute kidney injury in critically ill burn patients. Risk factors, progression and impact on mortality.Burns2010; 36: 205–211.
25.
CruzD.N., RicciZ., RoncoC.Clinical review: RIFLE and AKIN-time for reappraisal.Crit Care2009; 13: 211.
26.
UdyA.A., RobertsJ.A., BootsR.J., PatersonD.L., LipmanJ.Augmented renal clearance: implications for antibacterial dosing in the critically ill.Clin Pharmacokinet2010; 49: 1–16.
27.
UdyA.A., RobertsJ.A., LipmanJ.Implications of augmented renal clearance in critically ill patients.Nat Rev Nephrol2011; 7: 539–543.
28.
LiJ., UdyA.A., KirkpatrickC.M.J., LipmanJ., RobertsJ.A.Improving vancomycin prescription in critical illness through a drug use evaluation process: a weight-based dosing intervention study.Int J Antimicrob Agents2012; 39: 69–72.
